Cargando…

Time to immunologic recovery and determinant factors among adults who initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia

BACKGROUND: CD4 cells are the major targets for human immunodeficiency virus (HIV) and treatment with Antiretroviral Therapy (ART) influences the CD4 cell count of HIV patients. In addition to ART, the time required to reach normal range of CD4 counts (500 cells/mm(3)) can be affected by clinical, s...

Descripción completa

Detalles Bibliográficos
Autores principales: Gezie, Lemma Derseh, Gelaye, Kassahun Alemu, Worku, Abebaw Gebeyehu, Ayele, Tadesse Awoke, Teshome, Destaw Fetene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512981/
https://www.ncbi.nlm.nih.gov/pubmed/28705176
http://dx.doi.org/10.1186/s13104-017-2602-0
_version_ 1783250567870545920
author Gezie, Lemma Derseh
Gelaye, Kassahun Alemu
Worku, Abebaw Gebeyehu
Ayele, Tadesse Awoke
Teshome, Destaw Fetene
author_facet Gezie, Lemma Derseh
Gelaye, Kassahun Alemu
Worku, Abebaw Gebeyehu
Ayele, Tadesse Awoke
Teshome, Destaw Fetene
author_sort Gezie, Lemma Derseh
collection PubMed
description BACKGROUND: CD4 cells are the major targets for human immunodeficiency virus (HIV) and treatment with Antiretroviral Therapy (ART) influences the CD4 cell count of HIV patients. In addition to ART, the time required to reach normal range of CD4 counts (500 cells/mm(3)) can be affected by clinical, socio-demographic, and behavioral factors. This retrospective cohort study was conducted to determine the incidence of having the normal range of CD4 cell counts and factors that affect the time required to reach this normal range among adult HIV patients who initiated into ART. METHODS: Data of 4 years were retrospectively retrieved from routinely registered characteristics of 937 ART users enrolled in 2010. Survival time until immunologic recovery and its determinant factors were examined using the frailty model with different parametric distributions alternatively. RESULTS: Most (80.8%) of the ART attendants had CD4 cell count of 200 cells/mm(3) or less at initiation. The overall incidence rate of immunologic recovery was 12.67 persons per 1000 person-months (95% CI 11.30, 14.20). The dependency of frailties of immunologic recovery by residence was statistically significant (Theta = 0.05, p value = 0.006). Baseline age (Adjusted Hazard Ratio (AHR) = 0.98, 95% CI 0.97, 0.99), baseline CD4 count (AHR = 1.006, 95% CI 1.005, 1.008), and female sex (AHR = 1.34, 95% CI 1.03, 1.73) were significantly associated with shorter survival time for immunologic recovery. CONCLUSION: Higher baseline CD4 count, lower baseline age, and female sex were positively associated with the time to immunologic recovery, which also dependent on proximity/residence of ART users. Therefore, further scale up of ART services with due emphasis to patients with low CD4 count at baseline particularly for male and older ART users are recommended to reach the normal range of CD4 count in a shorter time of treatment.
format Online
Article
Text
id pubmed-5512981
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55129812017-07-19 Time to immunologic recovery and determinant factors among adults who initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia Gezie, Lemma Derseh Gelaye, Kassahun Alemu Worku, Abebaw Gebeyehu Ayele, Tadesse Awoke Teshome, Destaw Fetene BMC Res Notes Research Article BACKGROUND: CD4 cells are the major targets for human immunodeficiency virus (HIV) and treatment with Antiretroviral Therapy (ART) influences the CD4 cell count of HIV patients. In addition to ART, the time required to reach normal range of CD4 counts (500 cells/mm(3)) can be affected by clinical, socio-demographic, and behavioral factors. This retrospective cohort study was conducted to determine the incidence of having the normal range of CD4 cell counts and factors that affect the time required to reach this normal range among adult HIV patients who initiated into ART. METHODS: Data of 4 years were retrospectively retrieved from routinely registered characteristics of 937 ART users enrolled in 2010. Survival time until immunologic recovery and its determinant factors were examined using the frailty model with different parametric distributions alternatively. RESULTS: Most (80.8%) of the ART attendants had CD4 cell count of 200 cells/mm(3) or less at initiation. The overall incidence rate of immunologic recovery was 12.67 persons per 1000 person-months (95% CI 11.30, 14.20). The dependency of frailties of immunologic recovery by residence was statistically significant (Theta = 0.05, p value = 0.006). Baseline age (Adjusted Hazard Ratio (AHR) = 0.98, 95% CI 0.97, 0.99), baseline CD4 count (AHR = 1.006, 95% CI 1.005, 1.008), and female sex (AHR = 1.34, 95% CI 1.03, 1.73) were significantly associated with shorter survival time for immunologic recovery. CONCLUSION: Higher baseline CD4 count, lower baseline age, and female sex were positively associated with the time to immunologic recovery, which also dependent on proximity/residence of ART users. Therefore, further scale up of ART services with due emphasis to patients with low CD4 count at baseline particularly for male and older ART users are recommended to reach the normal range of CD4 count in a shorter time of treatment. BioMed Central 2017-07-14 /pmc/articles/PMC5512981/ /pubmed/28705176 http://dx.doi.org/10.1186/s13104-017-2602-0 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Gezie, Lemma Derseh
Gelaye, Kassahun Alemu
Worku, Abebaw Gebeyehu
Ayele, Tadesse Awoke
Teshome, Destaw Fetene
Time to immunologic recovery and determinant factors among adults who initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia
title Time to immunologic recovery and determinant factors among adults who initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia
title_full Time to immunologic recovery and determinant factors among adults who initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia
title_fullStr Time to immunologic recovery and determinant factors among adults who initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia
title_full_unstemmed Time to immunologic recovery and determinant factors among adults who initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia
title_short Time to immunologic recovery and determinant factors among adults who initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia
title_sort time to immunologic recovery and determinant factors among adults who initiated art in felege hiwot referral hospital, northwest ethiopia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512981/
https://www.ncbi.nlm.nih.gov/pubmed/28705176
http://dx.doi.org/10.1186/s13104-017-2602-0
work_keys_str_mv AT gezielemmaderseh timetoimmunologicrecoveryanddeterminantfactorsamongadultswhoinitiatedartinfelegehiwotreferralhospitalnorthwestethiopia
AT gelayekassahunalemu timetoimmunologicrecoveryanddeterminantfactorsamongadultswhoinitiatedartinfelegehiwotreferralhospitalnorthwestethiopia
AT workuabebawgebeyehu timetoimmunologicrecoveryanddeterminantfactorsamongadultswhoinitiatedartinfelegehiwotreferralhospitalnorthwestethiopia
AT ayeletadesseawoke timetoimmunologicrecoveryanddeterminantfactorsamongadultswhoinitiatedartinfelegehiwotreferralhospitalnorthwestethiopia
AT teshomedestawfetene timetoimmunologicrecoveryanddeterminantfactorsamongadultswhoinitiatedartinfelegehiwotreferralhospitalnorthwestethiopia